Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OCERA THERAPEUTICS INC

Home Clinical Trial Sponsors and OrganizationsOCERA THERAPEUTICS INC

OCERA THERAPEUTICS INC

555 Twin Dolphin Dr Ste 615, Redwood City, California, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

10

10 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

10

100.0%

Trial Status Distribution

Active, not recruiting

10

100.0%

Clinical Trials

Trials sponsored by this organization (10)

A multicenter, randomized clinical study to see how efficient, safe and well tolerated OCR-002 new drug candidate is in patients who suffer from cirrhosis and high ammonia level in blood with an onset of encephalopathy caused by abnormal liver activity

Active, not recruiting

Oct 2014234 participants

A multicenter, randomized clinical study to see how efficient, safe and well tolerated OCR-002 new drug candidate is in patients who suffer from cirrhosis and high ammonia level in blood with an onset of encephalopathy caused by abnormal liver activity

Active, not recruiting

Oct 2014140 participants

A multicenter, randomized clinical study to see how efficient, safe and well tolerated OCR-002 new drug candidate is in patients who suffer from cirrhosis and high ammonia level in blood with an onset of encephalopathy caused by abnormal liver activity

Active, not recruiting

Sep 2014140 participants

A multicenter, randomized clinical study to see how efficient, safe and well tolerated OCR-002 new drug candidate is in patients who suffer from cirrhosis and high ammonia level in blood with an onset of encephalopathy caused by abnormal liver activity

Active, not recruiting

Sep 2014234 participants

A multicenter, randomized clinical study to see how efficient, safe and well tolerated OCR-002 new drug candidate is in patients who suffer from cirrhosis and high ammonia level in blood with an onset of encephalopathy caused by abnormal liver activity

Active, not recruiting

Aug 2014234 participants

Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy,Safety and Tolerability of OCR-002 (ornithine phenylacetate) inHospitalized Patients with Cirrhosis and AssociatedHyperammonemia with an Episode of Hepatic Encephalopathy - STOP-HE study

Active, not recruiting

Aug 2014231 participants

A multicenter, randomized clinical study to see how efficient, safe and well tolerated OCR-002 new drug candidate is in patients who suffer from cirrhosis and high ammonia level in blood with an onset of encephalopathy caused by abnormal liver activity

Active, not recruiting

Jul 2014234 participants

A multicenter, randomized clinical study to see how efficient, safe and well tolerated OCR-002 new drug candidate is in patients who suffer from cirrhosis and high ammonia level in blood with an onset of encephalopathy caused by abnormal liver activity

Active, not recruiting

Jul 2014234 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials10
Approvals
News

Back to Organizations